Cardiac Dimensions said today that the FDA granted an investigational device exemption for a pivotal trial of its Carillon mitral valve repair device.
Kirkland, Wash.-based Cardiac Dimensions said the 400-patient study will compare the device with guideline-directed treatment of symptomatic functional mitral regurgitation associated with heart failure after a year.
